NeuroPace, Inc.
NPCEHealthcareNASDAQMedical Devices · Last scanned May 30, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, NeuroPace, Inc. focuses on Medical Devices services and products. NeuroPace, Inc. operates as a medical device company in the United States. The $563.9M market capitalization puts NPCE squarely in small-cap range for its industry. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy.
Market Cap
$563.9M
Beta
1.93
P/E (TTM)
—
P/E (Fwd)
-55.64
EPS (TTM)
$-0.65
EPS (Fwd)
$-0.30
ROE
-111.4%
ROA
-10.0%
Cash
$54.0M
Total Debt
$70.5M
Free CF
-$2.7M
52W Change
26.8%
Annual Financials
Cash vs Debt
On the balance sheet, NPCE has $54.0M in cash with $70.5M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$2.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -111.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $45.5M (2022) to $100.0M (2025), reflecting a 120% increase over the period.
A beta of 1.93 means NPCE is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing NPCE's risk profile alongside its fundamentals and technical indicators provides a more complete picture.